Biogen
Biogen swoops to appoint Ex-Roche Vice President
March 16, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen
Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated …
NICE reverses decision on medication for relapsing multiple sclerosis
March 16, 2017Sales and Marketing Biogen, zinbryta
The current topic of discussion regarding NICE is how its recent changes will impact patient access to medicine but, away …
UK High Court rules against AbbVie’s Humira patents
March 6, 2017Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar
The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …
Biogen shells out $1.25bn to protect best-selling MS drug
January 18, 2017Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera
Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …
Biogen’s gains late-year drug approval first for controversially expensive drug
January 3, 2017Manufacturing and Production, Sales and Marketing Biogen, FDA
The FDA squeezed in one last approval before the year ended with the first approval for a drug to treat …
Neurodegenerative market to be worth $45 billion by 2022
December 12, 2016Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative
Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …
Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint
November 7, 2016Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …
Biogen closes in on bringing muscular atrophy preventing drug to market
September 26, 2016Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen
Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …
FDA fast track designation for Biogen’s investigational Alzheimer’s treatment
September 2, 2016Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track
Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …
Biogen names haemophilia spin-off Bioverativ
August 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ
Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …
Takeover rumours send Biogen’s stock soaring
August 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover
Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …
Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III
August 2, 2016Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …
George Scangos to step down as Biogen CEO
July 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos
In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …
Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis
July 7, 2016Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta
Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …
Weekly Movers: Lion Biotech, Adamis, Sarepta…
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta
Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …
Latest content
